IAR134 / Innovent Biologics - LARVOL DELTA

The development of adipose delivery method for ALK7 siRNA (IAR134) to enable high quality weight control for monotherapy and combo with GLP-1 analogue (EASD 2026) - "IAR134 showed the potential as a quality weigh loss medicine because of the following: (1) Significantly reduces weight in DIO mouse model (2) More powerful in combo with GLP-1 RA than GLP-1 RA single agent (3) More durable than high dose GLP-1 RA after treatment withdrawal (4) More fat mass loss, less lean mass loss than GLP-1 RA"

Monotherapy • Metabolic Disorders • Obesity • GCG